Takis
Desconocido
ARDAT: Accelerating Research Development for Advanced Therapies
TAKIS SRL
participó en un
H2020:
H2020-JTI-IMI2-2019-18-two-stage
Major current hurdles for wide clinical use of AAV vectors are attributable primarily to: (i) host elimination by both immune and non-immune...
2020-11-11 - 2025-10-31 | Financiado
2020-11-11 - 2025-10-31 | Financiado
Magicbullet Reloaded: Small Molecule Drug Conjugates for Targeted Delivery in Tumor Therapy
TAKIS SRL
participó en un
H2020:
H2020-MSCA-ITN-2019
"Despite the continuing development of new and more efficient treatments, cancer remains the second cause of premature death worldwide. Mult...
2019-09-11 - 2024-04-30 | Financiado
2019-09-11 - 2024-04-30 | Financiado
TK-NEO: Personalized Cancer Immunotherapy through DNA EP vaccines
TAKIS SRL
tramitó un
H2020:
H2020-EIC-SMEInst-2018-2020
TK-NEO is a DNA-based Neoantigen Cancer Vaccine (NCV), for use as therapeutic vaccination in patients with locally advanced or metastatic so...
2019-07-25 - 2020-01-31 | Financiado
2019-07-25 - 2020-01-31 | Financiado
* No se disponen de datos de la empresa actual.